Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 4/20 | 0.58 |
| ▸ | SCD5 | Q86SK9 | 1/20 | 0.48 |
| ▸ | MGLL | Q99685 | 1/20 | 0.47 |
| ▸ | CHRM2 | P08172 | 7/20 | 0.46 |
| ▸ | CHRM3 | P20309 | 7/20 | 0.46 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.43 |
| ▸ | MTOR | P42345 | 1/20 | 0.43 |
| ▸ | NAMPT | P43490 | 1/20 | 0.43 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.41 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17328253 | 0.88 | SCD5 (0.48) | EPHX2SCD5GPR119L3MBTL1POLB | |
| SCHEMBL17328213 | 0.84 | CHRM2 (0.56) | EPHX2SCD5MGLLCHRM2CHRM3 | |
| SCHEMBL19096874 | 0.84 | EPHX2 (0.62) | EPHX2MGLLCHRM2CHRM3L3MBTL1 | |
| SCHEMBL17328260 | 0.83 | GPR119 (0.45) | EPHX2SCD5GPR119L3MBTL1POLB | |
| SCHEMBL20025475 | 0.82 | GPR119 (0.59) | MGLLGPR119 | |
| SCHEMBL2142176 | 0.82 | CHRM2 (0.54) | EPHX2SCD5CHRM2CHRM3PIK3CA | |
| SCHEMBL1088005 | 0.81 | L3MBTL1 (0.69) | GPR119L3MBTL1POLB | |
| SCHEMBL2143363 | 0.81 | CHRM2 (0.61) | EPHX2SCD5CHRM2CHRM3PIK3CA | |
| SCHEMBL1247151 | 0.79 | CHRM2 (0.64) | SCD5MGLLCHRM2CHRM3PIK3CA | |
| SCHEMBL1246052 | 0.79 | CHRM2 (0.64) | EPHX2SCD5MGLLCHRM2CHRM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3149005-B1 | AMIDE DERIVATIVES OF 1-OXA-4,9-DIAZASPIRO UNDECANE COMPOUNDS HAVING MULTIMODAL ACTIVITY AGAINST PAIN | ESTEVE LABOR DR (ES) | 2018-04-18 | — | — | EP | disclosed |
| US-20170197984-A1 | AMIDE DERIVATIVES OF 1-OXA-4,9-DIAZASPIRO UNDECANE COMPOUNDS HAVING MULTIMODAL ACTIVITY AGAINST PAIN | ESTEVE PHARMACEUTICALS, S.A. (ES) | 2017-07-13 | — | — | US | disclosed |
| US-20170197984-A1 | AMIDE DERIVATIVES OF 1-OXA-4,9-DIAZASPIRO UNDECANE COMPOUNDS HAVING MULTIMODAL ACTIVITY AGAINST PAIN | ESTEVE PHARMACEUTICALS, S.A. (ES) | 2017-07-13 | — | — | US | disclosed |
| WO-2015185208-A1 | AMIDE DERIVATIVES OF 1-OXA-4,9-DIAZASPIRO UNDECANE COMPOUNDS HAVING MULTIMODAL ACTIVITY AGAINST PAIN | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2015-12-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170197984-A1 | AMIDE DERIVATIVES OF 1-OXA-4,9-DIAZASPIRO UNDECANE COMPOUNDS HAVING MULTIMODAL ACTIVITY AGAINST PAIN | OPRD1, SIGMAR1, OPRM1 | EPHX2 2094/4885SCD5 2111/4885MGLL 3651/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.